Table 4.
Cox proportional hazards analyses testing the count of CNV as a predictive variable for TTT
| Independent segments (n=14) |
Independent CLL-specific segments (n=3) |
|||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P variable | P overall model (Likelihood ratio test) | HR | 95% CI | P variable | P overall model (Likelihood ratio test) | |
| Count of CNV as a continuous variable | 2.1 | 1.7–2.7 | 6.1 × 10−12 | 2.1 × 10−12 | 1.5 | 1.2–1.9 | 0.0005 | 0.0006 |
| Count of CNV as a categorical variable | 5.9 × 10−13 | 0.0023 | ||||||
| 1 CNV | 1.9 | 0.9–4.2 | 0.0907 | 1.6 | 1.1–2.2 | 0.0131 | ||
| 2 CNV | 3.6 | 1.6–7.9 | 0.0014 | 2.2 | 1.3–3.7 | 0.0022 | ||
| 3 CNV | 9.5 | 4.2–21.7 | 9.1 × 10−8 | NA | NA | NA | ||
| Count of CNV as a continuous variable compared to unfavorable cytogenetics | 2.3 × -10−11∗ | 1.1 × 10−12 | 0.0014∗ | 2.6x10−5 | ||||
| Count of CNV | 2.1 | 1.67–2.59 | 6.7 × 10−11 | 1.5 | 1.2–1.9 | 0.0010 | ||
| Del11q22 and/or del17p13 | 1.6 | 1.04–2.40 | 0.0323 | 1.9 | 1.2–2.8 | 0.0032 | ||
| Count of CNV as a categorical variable compared to known prognostic variables | 1.7 × 10−7∗ | 5.4 × 10−14 | 0.0709∗ | 1.3 × 10−6 | ||||
| 1 CNV | 1.8 | 0.8–3.9 | 0.1478 | 1.3 | 0.9–1.9 | 0.1424 | ||
| 2 CNV | 2.9 | 1.3–6.6 | 0.0103 | 1.8 | 1.1–3.0 | 0.0262 | ||
| ≥3 CNV | 7.5 | 3.1–17.8 | 5.8 × 10−6 | NA | NA | NA | ||
| Unmutated IGHV status | 1.9 | 1.3–2.7 | 0.0013 | 2.2 | 1.5–3.2 | 2.0 × 10−5 | ||
| Del11q22 and/or dell7p13 | 1.2 | 0.8–1.8 | 0.3899 | 1.5 | 1.0–2.2 | 0.0820 | ||
| Lambda light chain use | 1.1 | 0.78–1.6 | 0.5507 | 1.4 | 1.0–2.0 | 0.0526 | ||
CI, confidence interval; HR, hazard ratio; n, number of patients; NA, not applicable; p, p-value.
∗
P-values for the significance of addition of the CNV count to clinical variables was tested using an analysis of deviance and is based on the chi- square statistic.